Test Research, Inc.

TWSE:3030 Stok Raporu

Piyasa değeri: NT$31.3b

Test Research Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Test Research şirketinin toplam hissedar öz sermayesi NT$7.4B ve toplam borcu NT$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$10.5B ve NT$3.1B dir. Test Research 'in FAVÖK'ü NT$1.7B faiz karşılama oranı -132.6 dur. Şirketin NT$1.7B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0%

Borç/özkaynak oranı

NT$0

Borç

Faiz karşılama oranı-132.6x
NakitNT$1.68b
EşitlikNT$7.35b
Toplam yükümlülüklerNT$3.12b
Toplam varlıklarNT$10.47b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Capital Investment Trends At Test Research (TWSE:3030) Look Strong

Oct 17
Capital Investment Trends At Test Research (TWSE:3030) Look Strong

Test Research, Inc.'s (TWSE:3030) Popularity With Investors Under Threat As Stock Sinks 27%

Aug 05
Test Research, Inc.'s (TWSE:3030) Popularity With Investors Under Threat As Stock Sinks 27%

Test Research (TWSE:3030) May Have Issues Allocating Its Capital

Jul 11
Test Research (TWSE:3030) May Have Issues Allocating Its Capital

Test Research (TWSE:3030) Has Announced That Its Dividend Will Be Reduced To NT$3.30

Jun 01
Test Research (TWSE:3030) Has Announced That Its Dividend Will Be Reduced To NT$3.30

Optimistic Investors Push Test Research, Inc. (TWSE:3030) Shares Up 67% But Growth Is Lacking

May 31
Optimistic Investors Push Test Research, Inc. (TWSE:3030) Shares Up 67% But Growth Is Lacking

Test Research, Inc.'s (TWSE:3030) 25% Share Price Surge Not Quite Adding Up

Apr 15
Test Research, Inc.'s (TWSE:3030) 25% Share Price Surge Not Quite Adding Up

Is Test Research, Inc. (TPE:3030) A Smart Choice For Dividend Investors?

Mar 19
Is Test Research, Inc. (TPE:3030) A Smart Choice For Dividend Investors?

With EPS Growth And More, Test Research (TPE:3030) Is Interesting

Mar 01
With EPS Growth And More, Test Research (TPE:3030) Is Interesting

Should You Invest In Test Research (TPE:3030)?

Feb 11
Should You Invest In Test Research (TPE:3030)?

Test Research (TPE:3030) Has Compensated Shareholders With A Respectable 70% Return On Their Investment

Jan 24
Test Research (TPE:3030) Has Compensated Shareholders With A Respectable 70% Return On Their Investment

Is Test Research, Inc.'s (TPE:3030) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 05
Is Test Research, Inc.'s (TPE:3030) Latest Stock Performance Being Led By Its Strong Fundamentals?

Is Test Research, Inc. (TPE:3030) A Good Dividend Stock?

Dec 18
Is Test Research, Inc. (TPE:3030) A Good Dividend Stock?

Here's Why I Think Test Research (TPE:3030) Is An Interesting Stock

Nov 30
Here's Why I Think Test Research (TPE:3030) Is An Interesting Stock

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 3030 'nin kısa vadeli varlıkları ( NT$6.3B ) kısa vadeli yükümlülüklerini ( NT$2.8B ) aşıyor.

Uzun Vadeli Yükümlülükler: 3030 şirketinin kısa vadeli varlıkları ( NT$6.3B ) uzun vadeli yükümlülüklerini ( NT$271.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 3030 borçsuzdur.

Borcun Azaltılması: 3030 son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: 3030 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 3030 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Bilanço

Sağlıklı şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y